 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | censavudine (TPN-101) / Transposon Therap, Yale University
Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: TPN-101 in Aicardi-Gouti (clinicaltrials.gov) - Apr 4, 2025
P2, N=16, Active, not recruiting, Sponsor: Transposon Therapeutics, Inc.
Recruiting --> Active, not recruiting | Phase classification: P2a --> P2 | Trial completion date: Apr 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- censavudine (TPN-101) / Transposon Therap, Yale University, BMS
A Phase 2A study of TPN-101, a nucleoside reverse transcriptase inhibitor, in patients witH C9ORF72-related ALS/FTD (Poster Hall at the Palais de Congres Montreal; 517b/c) - Nov 7, 2024 - Abstract #ALSMND2024ALS_MND_585;
TPN-101 was well-tolerated in participants with C9ORF72-HRE ALS/FTD. Biomarker and clinical effects provide evidence that TPN-101 may have disease-modifying effects in patients with these disorders and support advancing to larger studies.
- || Review, Journal: Current status of the small molecule anti-HIV drugs in the pipeline or recently approved. (Pubmed Central) - Aug 22, 2024
There is a considerable progress in the development of new anti-HIV drugs and the effort will continue since HIV infections has no cure or vaccine till now. Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance.
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Trial completion date, Trial primary completion date: A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Jul 13, 2023
P2a, N=40, Active, not recruiting, Sponsor: Transposon Therapeutics, Inc.
Efforts are needed to reduce the toxicity of available drugs or discover new drugs with new classes which can delay the development of resistance. Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023
- || censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment open: TPN-101 in Aicardi-Gouti (clinicaltrials.gov) - Mar 31, 2023
P2a, N=16, Recruiting, Sponsor: Transposon Therapeutics, Inc.
Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Jul 2023 --> Dec 2023 Not yet recruiting --> Recruiting
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Trial initiation date: TPN-101 in Aicardi-Gouti (clinicaltrials.gov) - Mar 7, 2023
P2a, N=16, Not yet recruiting, Sponsor: Transposon Therapeutics, Inc.
Not yet recruiting --> Recruiting Initiation date: Dec 2022 --> Mar 2023
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment closed: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD (clinicaltrials.gov) - Mar 6, 2023
P2a, N=42, Active, not recruiting, Sponsor: Transposon Therapeutics, Inc.
Initiation date: Dec 2022 --> Mar 2023 Recruiting --> Active, not recruiting
- || censavudine (TPN-101) / Transposon Therap, Yale University, BMS
New P2a trial: TPN-101 in Aicardi-Gouti (clinicaltrials.gov) - Nov 14, 2022
P2a, N=16, Not yet recruiting, Sponsor: Transposon Therapeutics, Inc.
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment closed: A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Aug 11, 2022
P2a, N=40, Active, not recruiting, Sponsor: Transposon Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | censavudine (TPN-101) / Transposon Therap
Journal: Synthesis of Carbon-14 and Stable Isotope Labeled Censavudine. (Pubmed Central) - Apr 6, 2022
Deuterium labeled Censavudine was synthesized in two steps in a 68% overall yield from [D ]-thymine. A total of 237 mg were prepared with a UV purity of 99%.
- | Journal: 4'-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives. (Pubmed Central) - Feb 19, 2022
P=N/A, P3
FNC cured the COVID-19 disease in almost all patients and showed better therapeutic efficacy than remdesivir. In this Account, we provide an overview of 4'-modified nucleoside analogs in clinical stages for antiviral therapies, highlighting the drug discovery strategies, structure-activity relationship studies, and preclinical/clinical studies and also give our perspectives on nucleoside-based antiviral drug discovery.
- || censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment open: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD (clinicaltrials.gov) - Dec 3, 2021
P2a, N=40, Recruiting, Sponsor: Transposon Therapeutics, Inc.
In this Account, we provide an overview of 4'-modified nucleoside analogs in clinical stages for antiviral therapies, highlighting the drug discovery strategies, structure-activity relationship studies, and preclinical/clinical studies and also give our perspectives on nucleoside-based antiviral drug discovery. Not yet recruiting --> Recruiting
- || censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment open: A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Sep 28, 2021
P2a, N=40, Recruiting, Sponsor: Transposon Therapeutics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
New P2a trial: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD (clinicaltrials.gov) - Aug 5, 2021
P2a, N=40, Not yet recruiting, Sponsor: Transposon Therapeutics, Inc.
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
New P2a trial: A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) (clinicaltrials.gov) - Aug 5, 2021
P2a, N=40, Not yet recruiting, Sponsor: Transposon Therapeutics, Inc.
- | censavudine (OBP-601) / Oncolys BioPharma, Vemlidy (tenofovir alafenamide) / Gilead
Preclinical, Journal: In vitro evaluation of novel reverse transcriptase inhibitors TAF and OBP-601 against multi-drug resistant primary isolates of HIV-2. (Pubmed Central) - Feb 14, 2020
With one exception, all resistant viruses had canonical NRTIs-associated resistance mutations (K65R, N69S, V111I, Y115F, Q151M and M184V). Our results show that TAF and OBP-601 have potent activity against multi-drug resistant HIV-2 isolates and should be considered for the treatment of HIV-2 infected patients failing therapy.
- | censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Trial termination: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - Jul 15, 2014
P2b, N=301, Terminated, Sponsor: Bristol-Myers Squibb
Our results show that TAF and OBP-601 have potent activity against multi-drug resistant HIV-2 isolates and should be considered for the treatment of HIV-2 infected patients failing therapy. Active, not recruiting --> Terminated
- ||| censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment closed: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - Jul 1, 2014
P2b, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- ||| censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Trial initiation date: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Initiation date: Jan 2012 --> Feb 2011
- || censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Trial completion date: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2012 --> Feb 2011 Trial completion date: Aug 2017 --> Aug 2014
- |||| censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment open: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - May 6, 2014
P2b, N=300, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Aug 2017 --> Aug 2014 Active, not recruiting --> Recruiting
- ||| censavudine (TPN-101) / Transposon Therap, Yale University, BMS
Enrollment change: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - Dec 14, 2011
P2b, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting N=400 --> 300
- |||||| censavudine (TPN-101) / Transposon Therap, Yale University, BMS
New P2b trial: Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive (clinicaltrials.gov) - Dec 7, 2011
P2b, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb